Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio
September 20 2016 - 6:59AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an
innovative, shared laboratory space designed as a launch pad for
life-sciences and biotech startups, today announced that PanTher
and Suono Bio are the winners of Bristol-Myers Squibb’s Golden
Tickets for LabCentral. As a platinum sponsor of LabCentral,
Bristol-Myers Squibb can select up to two innovative life-sciences
and biotech startup companies per year of active sponsorship for
“Golden Tickets,” which underwrite the cost of one lab bench for
one year in LabCentral’s Kendall Square facility.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160920005584/en/
“PanTher and Suono Bio are working to deliver innovative
technologies that have the potential to impact patients with
serious diseases, and we’re pleased that the Golden Tickets will
enable them to advance their research,” said Carl Decicco, Ph.D.,
Head of Discovery at Bristol-Myers Squibb. “Our sponsorship of
LabCentral, and the awarding of Golden Tickets to these two
companies, align with our strategy to encourage scientific
innovations in our disease areas of focus, from academia through
early development.”
“Bristol-Myers Squibb has made an excellent selection of its
first two Golden Ticket winners – we know them both well,”
commented LabCentral Co-Founder and President Johannes Fruehauf,
M.D., Ph.D. “Both have the potential to make major inroads against
devastating diseases using novel approaches to drug delivery. We
are excited to have them join in the vibrant ecosystem of the
LabCentral community and look forward to watching as these
companies move down the path toward success.”
A pre-clinical-stage company, PanTher Therapeutics is working to
revolutionize the treatment of inoperable, locally advanced solid
tumors − studying the direct delivery of existing, already proven
chemotherapy agents directly onto the tumor for consistent, slow
release over time. The company designed its novel delivery method
to potentially eliminate the toxicity and debilitating side effects
that chemo agents can produce when delivered systemically through
traditional IV or oral administration. Its first potential
indication is pancreatic cancer, a particularly lethal disease that
affects more than 53,000 Americans annually, where excruciating
symptoms arise from the primary mass invading nearby vital organs.
By changing the route of administration to target just the tumor,
PanTher is designed to increase the amount of drug reaching the
intended destination with the aim to enhance therapeutic efficacy.
Eliminating adverse outcomes may also help to lower healthcare
costs. Pancreatic cancer accounts for about three percent of all
cancers in the U.S. and about seven percent of cancer deaths. A
privately held company, PanTher is completing pre-clinical studies
prior to initiating human trials and exploring opportunities for
partnerships to expand its product pipeline.
Suono Bio, a preclinical stage company, has developed
breakthrough technology − the “SuonoCalmTM” system − designed to
potentially enable ultra-rapid delivery of therapeutics across
tissues, including the gastrointestinal (GI) tract. Preclinical
studies have demonstrated that the ultrasound-based technology can
deliver small molecules, proteins, and nucleic acids locally and
systemically, validating further study of the SuonoCalm system.
Designed as an easy-to-use device to enable patients to
self-administer medication at home, the SuonoCalm technology may
also be applicable to a broad set of conditions outside of the GI
tract.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
About LabCentral (www.labcentral.org ; twitter
@labcentral)
A 28,000 square-foot facility in the heart of the Kendall
Square, Cambridge, Mass., a biotech innovation hub, LabCentral is a
first-of-its-kind shared laboratory space designed as a launchpad
for high-potential life-sciences and biotech startups. It offers
fully permitted laboratory and office space for early-stage
companies comprising approximately 125 scientists and
entrepreneurs. LabCentral provides first-class facility and
administrative support, skilled laboratory personnel, a
domain-relevant expert speaker series—as well as the other critical
services and support that startups need to begin laboratory
operations on day one. A private, nonprofit institution, LabCentral
was funded in part by a $5 million grant from the Massachusetts
Life Sciences Center, with support from its real-estate partner,
MIT. Founding sponsors include Triumvirate Environmental and
Johnson & Johnson Innovation.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2015 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160920005584/en/
Bristol-Myers SquibbMedia:Chrissy Trank,
609-252-5609christina.trank@bms.comorInvestors:Bill Szablewski,
609-252-5894william.szablewski@bms.comorLabCentralCaroline
Grossman, 781-771-5579cgrossman@labcentral.org
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024